Gastric cancer, as a multifactorial disorders, shows cytological and architectural heterogeneity compared to other gastrointestinal cancers, making it therapeutically challenging. Cisplatin is generally used in clinic for gastric cancer treatment but with toxic side effects and develops resistance. Anti-tumor properties of copper and its coordinated compounds have been explored intensively in recent years. In this study, we synthesized a novel Schiff base copper coordinated compound (SBCCC) and examined its antitumor effects in two gastric cancer cell lines SGC-7901 and BGC-823 as well as a mouse model of gastric cancer. The results show that SBCCC can significantly inhibit the proliferation of gastric cancer cells in a dose- and time-dependent manner. The IC50 of SBCCC in SGC-7901 and BGC-823 cells is 1 μM, which is much less than cisplatin’s IC50. SBCCC induces apoptosis and causes cell cycle arrest at the G1 phase. SBCCC induces apoptosis via multiple pathways including inhibition of NF-κB, ROS production and autophagy. The synthesized SBCCC induced cancer cell death via inhibition of NF-κB, ROS production and autophagy. The multiple cell-killing mechanisms were important to overcome therapeutic failure because of multidrug-resistance of cancer cells. SBCCC, with a lower IC50 compared to cisplatin, could render it the potential to overcome the side-effect for clinical application.
                                    胃癌是一种多因素疾病,与其他胃肠道癌症相比,它在细胞学和结构上具有异质性,因此在治疗上具有挑战性。
顺铂通常用于胃癌的临床治疗,但会产生毒副作用并产生耐药性。近年来,人们对
铜及其配位化合物的抗肿瘤特性进行了深入探讨。本研究合成了一种新型希夫碱
铜配位化合物(SBCCC),并在两种胃癌
细胞系 SGC-7901 和 BGC-823 以及胃癌小鼠模型中考察了其抗肿瘤作用。结果表明,SBCCC 能显著抑制胃癌细胞的增殖,其抑制作用呈剂量和时间依赖性。SBCCC 对 SGC-7901 和 BGC-823 细胞的 IC50 为 1 μM,远低于
顺铂的 IC50。SBCCC 可诱导细胞凋亡,并使细胞周期停滞在 G1 期。SBCCC 通过多种途径诱导细胞凋亡,包括抑制 NF-κB、产生 ROS 和自噬。合成的 SBCCC 可通过抑制 NF-κB、ROS 生成和自噬诱导癌
细胞死亡。多种细胞杀伤机制对于克服因癌细胞对多种药物产生耐药性而导致的治疗失败非常重要。与
顺铂相比,SBCCC 的 IC50 更低,因此有可能克服副作用,应用于临床。